z-logo
Premium
Utility and cost of low‐vacuum reinfusion drains in patients undergoing surgery for subcapital hip fracture repair. A before and after cohort study
Author(s) -
Muñoz M.,
Iglesias D.,
GarciaErce J. A.,
Cuenca J.,
Herrera A.,
MartinMontañez E.,
Pavia J.
Publication year - 2014
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/vox.12071
Subject(s) - medicine , blood transfusion , surgery , erythropoietin , hip fracture , cohort , anemia , blood loss , anesthesia , iron sucrose , blood management , intravenous iron , iron deficiency , osteoporosis
Background Postoperative blood loss may be a risk factor for allogeneic blood transfusion ( ABT ) in patients undergoing subcapital hip fracture ( SHF ) repair. We investigated the utility and costs of using a low‐vacuum reinfusion drain (Bellovac ABT ) within a blood management protocol for reducing ABT requirements in consecutive SHF . Methods The blood management protocol consisted of the application of a restrictive transfusion trigger (Hb < 8 g/dl), the peri‐operative administration of IV iron sucrose (3 × 200 mg/48 h) ± recombinant erythropoietin (1 × 40 000 IU sc) and the use of Bellovac ABT (Group 2, n  = 117). An immediate previous SHF series managed without Bellovac ABT served as control (Group 1, n  = 138). Results Overall, 72 out of 255 (28%) received at least one ABT unit (2·1 ± 1·0 U/transfused patient) without differences between groups. However, in the subgroup of patients with admission Hb < 13 g/dl, the use of Bellovac ABT reduced postoperative ABT rates (16% vs. 46%, for groups 2 and 1, respectively; P  = 0·001), although only 3 were reinfused, and was cost‐saving. The use of Bellovac ABT also resulted in fewer wound bleeding complications, but there were no differences in Hb at postoperative days 7 and 30 between groups. Conclusions In SHF patients with admission Hb < 13 g/dl and managed with peri‐operative IV iron ± recombinant erythropoietin plus restrictive transfusion indication, the use of Bellovac ABT was associated with reduced ABT requirements, without increasing postoperative complications, and cost‐savings.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here